Dengue Vaccines Market
Dengue Vaccines Market Overview 2025 to 2035
The global dengue vaccines market is on a strong growth trajectory, with an anticipated increase in valuation from USD 475.8 million in 2025 to USD 1,604.7 million by 2035, achieving a CAGR of 13.9% over the forecast period. This growth is driven by increasing incidences of dengue fever, rising global awareness about vaccine availability, and strong R&D initiatives by pharmaceutical giants.
Market Overview
Key Data Points
| Metric |
2025 Estimate |
2035 Forecast |
Growth Rate (CAGR) |
|---|---|---|---|
|
Market Value | USD 475.8 million | USD 1,604.7 million |
13.9% |
|
Major Regional Share (2025) |
Asia-Pacific (70%) |
Latin America (15%) |
– |
|
Leading Product Segment |
CYD-TDV (Dengvaxia) |
TAK-003 |
– |
Market Drivers and Trends
Key Growth Drivers:
- Global Dengue Burden: According to the World Health Organization, approximately 390 million dengue infections occur annually, with 70% of cases concentrated in Asia. The rising prevalence of dengue fever is propelling vaccine demand.
- New Vaccine Developments: Pharmaceutical companies, including Takeda and Sun Pharma, are introducing innovative vaccines such as TAK-003, which show promising efficacy across all dengue serotypes.
- International Collaborations: Partnerships like the Indo-US Vaccine Action Program are accelerating vaccine research, improving accessibility in endemic regions.
- Growing Awareness: Campaigns by governments and NGOs are raising public awareness, fostering early adoption of vaccination programs.
Emerging Trends:
- Technological Advancements: AI-powered research and monoclonal antibody developments are revolutionizing vaccine production.
- Affordable Vaccines: Initiatives aimed at reducing vaccine costs are expanding access in developing countries.
- Expanded Indications: New vaccines are being tailored to target broader age groups and high-risk populations.
Market Segmentation
By Product
- CYD-TDV (Dengvaxia)
- TAK-003
- VIS513 Monoclonal Antibody
By End-User
- Government Institutes
- Hospitals
- NGOs
By Region
| Region |
Market Share (2025) |
Key Growth Factors |
|---|---|---|
|
Asia-Pacific |
70% |
High dengue burden, regional R&D investments |
|
Latin America |
15% |
Active vaccination campaigns, rising incidence |
|
North America |
10% |
Regulatory approvals, new vaccine launches |
|
Europe |
5% |
Advanced healthcare infrastructure |
Challenges and Restraining Factors
- Limited Vaccine Availability: The market is still dominated by a single approved vaccine, Dengvaxia, with others under clinical trials.
- High Costs: Expensive vaccine production and distribution limit access in low-income regions.
- Complex Approval Processes: Regulatory hurdles delay the introduction of new vaccines in key markets.
Regional Insights
Asia-Pacific
The Asia-Pacific region is projected to dominate the market due to its high disease burden and strong presence of pharmaceutical companies like Takeda and Serum Institute of India. Countries such as India and Indonesia are investing heavily in vaccine research and public health campaigns.
Latin America
With 15% market share by 2025, countries like Brazil and Mexico are implementing mass vaccination programs to curb dengue outbreaks. Collaborations between local governments and global pharmaceutical companies are driving vaccine access.
Frequently Asked Questions
1. What is the market size forecast for 2035?
The market is expected to reach USD 1,604.7 million by 2035, growing at a CAGR of 13.9%.
2. Which product dominates the market?
CYD-TDV (Dengvaxia) remains the leading product, with TAK-003 gaining traction.
3. What are the major growth regions?
Asia-Pacific and Latin America are the key regions driving market growth.
Competitive Landscape
Leading players in the dengue vaccines market include:
- Sanofi Pasteur: Manufacturer of CYD-TDV (Dengvaxia), approved across 19 countries.
- Takeda Pharmaceutical Company: Developer of TAK-003, targeting all dengue serotypes.
- Merck & Co. Inc.: Partnering with Instituto Butantan for new vaccine candidates.
- Serum Institute of India: Innovating monoclonal antibody-based treatments.
Emerging companies like Sun Pharma and GeneOne Life Science are also contributing significantly to the market.
Contact our advisory team for detailed insights into established and emerging players.
Take Action Now!
Don’t miss the opportunity to capitalize on this growing market. Contact us today to access the full report and propel your business forward!